Biotech ETFs

Biotech ETFs invest in companies that develop drugs, therapies, and medical technologies using biological processes. The biotechnology sector is known for its high-reward, high-risk profile, as companies can see enormous gains from successful drug approvals or steep losses from clinical trial failures. Biotech ETFs help mitigate single-stock risk by spreading exposure across dozens or hundreds of biotech firms.

The leading biotech ETFs include IBB (iShares Biotechnology ETF), which tracks the NASDAQ Biotechnology Index with a large-cap tilt, XBI (SPDR S&P Biotech ETF), which uses an equal-weight methodology that gives smaller biotech companies significantly more representation, and ARKG (ARK Genomic Revolution ETF), an actively managed fund focused on genomics and gene-editing companies.

Biotech ETFs are well suited for investors with a long-term horizon who want exposure to pharmaceutical innovation, aging demographics, and breakthroughs in gene therapy, oncology, and rare diseases. The equal-weighted XBI tends to capture more upside from small-cap biotech rallies, while IBB offers more stability through its large-cap holdings. Consider your risk appetite when choosing between these approaches, and be prepared for periods of elevated volatility driven by regulatory decisions, patent expirations, and clinical data readouts.